- Home
- CAI vs CRL Comparison
CAI vs CRL Comparison
Compare CAI & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAI
- CRL
- Stock Information
- Founded
- CAI 2008
- CRL 1947
- Country
- CAI United States
- CRL United States
- Employees
- CAI N/A
- CRL N/A
- Industry
- CAI Medical Specialities
- CRL Biotechnology: Commercial Physical & Biological Resarch
- Sector
- CAI Health Care
- CRL Health Care
- Exchange
- CAI Nasdaq
- CRL Nasdaq
- Market Cap
- CAI 8.5B
- CRL 7.3B
- IPO Year
- CAI 2025
- CRL 2000
- Fundamental
- Price
- CAI $29.21
- CRL $167.70
- Analyst Decision
- CAI Strong Buy
- CRL Buy
- Analyst Count
- CAI 6
- CRL 16
- Target Price
- CAI $35.50
- CRL $190.86
- AVG Volume (30 Days)
- CAI 627.9K
- CRL 963.6K
- Earning Date
- CAI 11-05-2025
- CRL 11-05-2025
- Dividend Yield
- CAI N/A
- CRL N/A
- EPS Growth
- CAI N/A
- CRL N/A
- EPS
- CAI N/A
- CRL N/A
- Revenue
- CAI $533,847,000.00
- CRL $4,028,615,000.00
- Revenue This Year
- CAI $64.66
- CRL N/A
- Revenue Next Year
- CAI $45.81
- CRL $2.43
- P/E Ratio
- CAI N/A
- CRL N/A
- Revenue Growth
- CAI 106.53
- CRL N/A
- 52 Week Low
- CAI $25.40
- CRL $91.86
- 52 Week High
- CAI $42.50
- CRL $230.02
- Technical
- Relative Strength Index (RSI)
- CAI N/A
- CRL 38.27
- Support Level
- CAI N/A
- CRL $173.89
- Resistance Level
- CAI N/A
- CRL $180.19
- Average True Range (ATR)
- CAI 0.00
- CRL 6.58
- MACD
- CAI 0.00
- CRL -2.67
- Stochastic Oscillator
- CAI 0.00
- CRL 9.36
About CAI Caris Life Sciences Inc. Common Stock
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
About CRL Charles River Laboratories International Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.